Literature DB >> 12139736

Expression of cutaneous lymphocyte antigen is associated with a poor outcome of nasal-type natural killer-cell lymphoma.

Tadashi Yoshino1, Shigeo Nakamura, Junji Suzumiya, Nozomi Niitsu, Koichi Ohshima, Junjiro Tsuchiyama, Katsuji Shinagawa, Mitsune Tanimoto, Yoshito Sadahira, Mine Harada, Masahiro Kikuchi, Tadaatsu Akagi.   

Abstract

Nasal and nasal-type natural killer (NK) lymphoma is a distinct clinicopathological entity mostly associated with Epstein-Barr virus. Cases that have widespread lesions are resistant to ordinary anti-cancer therapy and take a highly aggressive course. To date, there are no available data on the relationships between the localization, clinical outcome and expression of adhesion molecules in such cases. We examined the expression of cutaneous lymphocyte antigen (CLA) in 52 cases of NK-cell lymphoma. CLA was highly expressed in cutaneous cases. Also, the CLA+ group (n=29) had a much worse prognosis than the CLA- group (n=23), regardless of the primary site or clinical staging. Univariate analysis identified some significant prognostic factors, and multivariate analysis of these factors showed that the expression of CLA was an independent prognostic indicator. In conclusion, the present findings established that CLA is an independent and important prognostic factor in patients with NK-cell lymphomas.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12139736     DOI: 10.1046/j.1365-2141.2002.03607.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  1 in total

1.  Prognostic biomarkers in patients with localized natural killer/T-cell lymphoma treated with concurrent chemoradiotherapy.

Authors:  Motoko Yamaguchi; Katsuyoshi Takata; Tadashi Yoshino; Naoki Ishizuka; Masahiko Oguchi; Yukio Kobayashi; Yasushi Isobe; Kenichi Ishizawa; Nobuko Kubota; Kuniaki Itoh; Noriko Usui; Kana Miyazaki; Izumi Wasada; Shigeo Nakamura; Yoshihiro Matsuno; Kazuo Oshimi; Tomohiro Kinoshita; Kunihiro Tsukasaki; Kensei Tobinai
Journal:  Cancer Sci       Date:  2014-10-04       Impact factor: 6.716

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.